References
- U.S. Food and Drug Administration USDoHaHS. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Rockville, MD: Food and Drug Administration; 1998.
- Agarwal A, Hassan M, Sepah YJ, Do DV, Nguyen QD. Subcutaneous repository corticotropin gel for non-infectious panuveitis: reappraisal of an old pharmacologic agent. Am J Ophthalmol Case Rep. 2016;4:78–82.
- Sharon Y, Chu DS. Adrenocorticotropic hormone gel for patients with non-infectious uveitis. Am J Ophthalmol Case Rep. 2019;15:100502.
- Oh D, Singh A, Kanu L, Lobo A, MacIntosh P, Bhat P. Outcomes of repository corticotropin gel for ocular sarcoidosis. Ocul Immunol Inflamm. 2020.
- Administration USFaD. Drug Approval Package. H.P. Acthar Gel (repository corticotropin) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022432s000lbl.pdf. Accessed June 25, 2020.
- DeVoe AG. A ten-year follow-up on a case of sympathetic ophthalmia. Trans Am Ophthalmol Soc. 1970;68:105–112.
- Fitzgerald JR, Bellows JG, Donegan JM, et al. Early clinical results of ACTH and cortisone treatment of ocular diseases. AMA Arch Ophthalmol. 1951;45(3):320–323.
- Gordon DM, McLean JM, Koteen H. Present status of corticotropin; ACTH, cortisone, and hydrocortisone in ophthalmology. Br J Ophthalmol. 1953;37:85–98.
- Nelson WW, Lima AF, Kranyak J, et al. Retrospective medical record review to describe use of repository corticotropin injection among patients with uveitis in the United States. J Ocul Pharmacol Ther. 2019;35(3):182–188.
- Baughman RP, Barney JB, O’Hare L, Lower EE. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016;110:66–72.
- Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23:905–912.
- Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther. 2011;5:381–389.
- Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195(3):313–322.
- Shakil S, Redberg RF. New (Very High) prices on old drugs. JAMA Intern Med. 2017;177:1568.
- Duarte-Garcia A, Matteson EL, Shah ND. Older drugs with limited trial evidence: are they worth the expense? The case of repository corticotropin marketed as H.P. Acthar Gel. Ann Intern Med. 2019;170:791–792.
- Metersky ML. Is there any reliable clinical evidence to suggest that Acthar is more effective than other forms of corticosteroids in treating sarcoidosis and other diseases it is being marketed to treat? Chest. 2016;149:886.
- Pollack A Questcor finds profits at $28,000 a vial. The New York Times. Web site. https://www.nytimes.com/2012/12/30/business/questcor-finds-profit-for-acthar-drug-at-28000-a-vial.html. Published 2012. Updated July 1, 2020. Accessed.
- Drash W Whistleblowers: company at heart of 97,000% drug price hike bribed doctors to boost sales. CNN Health. https://www.cnn.com/2019/04/30/health/mallinckrodt-whistleblower-lawsuit-acthar/index.html. Published 2019. Accessed July 10, 2020.
- Drug maker mallinckrodt agrees to pay over $15 million to resolve alleged false claims act liability for “wining and dining” doctors [press release]. 2019.
- Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN. Trends and characteristics of us medicare spending on repository corticotropin. JAMA Intern Med. 2017;177:1680–1682.
- https://openpaymentsdata.cms.gov/company/100000521814. Published 2019. Accessed July 21, 2020.